Spire RPM System
Predictive patient care platform with continuous cardiopulmonary monitoring
Platform · HybridCompany source
Company profile
About Wellinks
Wellinks is a digital healthcare company founded in 2012 and headquartered in New Haven, Connecticut, that specializes in chronic obstructive pulmonary disease (COPD) management and cardiopulmonary care. The company partners with health plans, providers, and value-based care organizations to deliver comprehensive virtual pulmonary care programs that bridge the gap between patients and healthcare providers. Wellinks' solution combines the Spire RPM (Remote Patient Monitoring) System with virtual pulmonary rehabilitation, one-on-one clinical coaching, 24/7 nurse triage, and personalized care management. The company recently acquired Spire Health, integrating cutting-edge patient monitoring technology to pioneer what they call "Predictive Patient Care." The Spire Tag is a lightweight wearable sensor that continuously tracks respiratory rate, heart rate, and activity levels, enabling early detection of exacerbations and proactive intervention. The company's clinical team includes certified health coaches, asthma educators, physicians, registered nurses, respiratory therapists, and clinical exercise physiologists who partner with patients to create evidence-based care plans. Wellinks addresses a critical gap in healthcare access: less than 4% of eligible COPD patients have access to pulmonary rehabilitation. Their virtual-first approach makes comprehensive respiratory care accessible and convenient, with appointments available in as little as two days. Wellinks serves multiple customer segments including Medicare Advantage plans, health insurers, health systems, risk-bearing entities, and primary care practices. The company has demonstrated significant clinical and economic outcomes, with research showing 45% fewer COPD-related ER visits, 65% reduction in hospitalizations, and average annual savings of $11,300 per patient. Wellinks operates primarily in the United States, with recent partnerships expanding their presence in New Jersey and Florida.
Company description Wellinks official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Wellinks?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- asthma
- cardiopulmonary conditions
- chronic obstructive pulmonary disease
- COPD
- respiratory diseases
Who it serves
- Health Insurers
- Health Systems
- Medicare Advantage Plans
- Primary Care Practices
- Risk Bearing Entities
- Value-Based Care Providers
Deployment & integration
Cloud Saas · Embedded · Hybrid deployment with recorded integration context.
Geographic context
MarketsConnecticut · Florida · New Jersey · United States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired Spire Health to integrate cutting-edge patient monitoring technology (2024-2025). Partnership with CareAbout Health announced March 2025 to expand into New Jersey and Florida markets serving over one million patients. Collaboration with SoNE HEALTH launched September 2024. Showcased Spire Tag technology at ATS 2025 International Conference in San Francisco.
Partnerships
Recorded partners
- CareAbout Health
- SoNE HEALTH (Southern New England Healthcare)
- Spire Health (acquired)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Spire Tag
Lightweight wearable sensor for continuous respiratory health monitoring
Device · EmbeddedCompany source
Wellinks Virtual COPD Management Program
Comprehensive virtual pulmonary care combining rehabilitation, remote monitoring, and personalized care management
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Investigation of the Impact of Wellinks on the Quality of Life and Clinical Outcomes in Patients With Chronic Obstructive Pulmonary Disease: Interventional Research Study.JMIR formative research · Feb 9, 2024
An Integrated, Multimodal, Digital Health Solution for Chronic Obstructive Pulmonary Disease: Prospective Observational Pilot Study.JMIR formative research · Mar 17, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
45% fewer COPD-related ER visits
Research-validated reduction in emergency department utilization
65% reduction in hospitalizations
Significant decrease in hospital admissions for COPD patients
$11,300 average annual savings per patient
Cost savings from reduced acute care episodes
CareAbout Health
Strategic partnership to expand value-based COPD management in New Jersey and Florida markets, supporting over one million patients
SoNE HEALTH (Southern New England Healthcare)
Collaboration to deliver high quality COPD care to patients in the SoNE HEALTH network through value-based care model
General COPD Patient Population
Reducing COPD-related emergency room visits and hospitalizations through virtual pulmonary care management
45% fewer COPD-related ER visits, 65% reduction in hospitalization, $11,300 average annual savings per patient
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Stacie Bratcher
Chief Executive Officer
06 · Company updates
Updates from Wellinks
Recent articles published on Wellinks's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.